Three Small Cap Names Over the Hump: SUPN, ENTB, and GEVO in Focus
Though the market looks tired today, we're seeing a few names show us hints of budding perkiness. Take a look at Entest BioMedical Inc. (PINK:ENTB). Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), and Gevo, Inc. (NASDAQ:GEVO). Those three names are the best of the best budding ideas today.
Owning Supernus Pharmaceuticals Inc. back in late November and early December was nothing less than miserable. Shares got whacked on November 30th after the float went through a major dilution. All that extra supply seems to have been burned off, however, as SUPN has made a string of higher highs and higher lows since early January, and is knocking on the door of a major resistance line. Indeed, it's already cleared it.
That line in the sand had been $7.79, where SUPN topped out a week and a half ago. The bulls never really changed their mind, though - they just needed to regroup and renew the effort. That's happened today, and with Supernus Pharmaceuticals now over the hump and trading at $7.81, there's little holding the stock back now.
If the name Gevo, Inc. rings a bell, it may be because I penned some bullish thoughts on the stock back on January 18th. Though the stock's been no less erratic since then, it's continued to make the forward progress I expected from it then. As of today though, (well, yesterday actually), GEVO has made it past the big stumbling block I had on my mind.
The nearby chart of GEVO says it all pretty well. The stock's been marching upward of late, largely fueled by new support at the 20-day moving average line, but also largely capped by resistance at the 100-day moving average line. That's not the case anymore, however. With yesterday's shove, Gevo, Inc. has blasted past the 100-day line to put the finishing touches on a major breakout effort. It's still going to be volatile, but it's clearly a bullish volatility.
Finally, it may not look like all that much with just a quick glance, but Entest BioMedical Inc. is subtly, quietly acting like it wants to hit the gas. Today's pop is the second one in just a little over two weeks that's pushed ENTB above the 100-day moving average line (see below). With a string of higher lows since then backing it up, this one may well be the one that sticks... and shakes the stock out or a long-term rut.
ENTB had been getting traction of late not on any official news (or even any media commentary), but rather, solely on buzz and whispers that suggest the worst is over, and the stock can only go up from here. It may sound crazy - if not impossible - to think Entest BioMedical has any real upside. But, charts don't lie.... somebody thinks something bullish about the company. Thing is, these unknown buying sprees have a tendency to be justified later on. It's worth watching anyway.